<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013687</url>
  </required_header>
  <id_info>
    <org_study_id>FhCMB Pfs25-001</org_study_id>
    <nct_id>NCT02013687</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer, Center for Molecular Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraunhofer, Center for Molecular Biotechnology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate
      the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With at Least One Adverse Event</measure>
    <time_frame>336 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects With Solicited Systemic Adverse Events</measure>
    <time_frame>336 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects With Solicited Local Adverse Events</measure>
    <time_frame>336 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Anti-Pfs25 IgG Following the Third Immunization.</measure>
    <time_frame>196 days</time_frame>
    <description>Serum anti-Pfs25 antibody IgG titers determined using an ELISA unit assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</measure>
    <time_frame>84 days</time_frame>
    <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), one month after the second vaccination (Study Day 84) in either the 30 μg or 100 μg dose groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</measure>
    <time_frame>196 days</time_frame>
    <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), showing ≥80% reduction of oocysts in Anopheles mosquito gut in ≥50% of the subjects with Study Day 196 sera (one month after the third vaccination) (Study Day 196) in either the 30 μg or 100 μg dose groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>2 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pfs25 VLP- FhCMB</intervention_name>
    <arm_group_label>2 µg + Alhydrogel</arm_group_label>
    <arm_group_label>10 µg + Alhydrogel</arm_group_label>
    <arm_group_label>30 µg + Alhydrogel</arm_group_label>
    <arm_group_label>100 µg + Alhydrogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female aged 18 - 50 years inclusive

          -  Able to give written informed consent obtained prior to screening

          -  Healthy, as determined by medical history, physical examination, vital signs, and
             clinical safety laboratory examinations at baseline

          -  Women of childbearing potential must have a negative urine pregnancy test within 24
             hours preceding receipt of each dose.

          -  Females should fulfill one of the following criteria:

               1. At least one year post-menopausal

               2. Surgically sterile

               3. Willing to use oral, implantable, transdermal or injectable contraceptives for 30
                  days prior to first vaccination and then for the study duration

               4. Willing to abstain from sexual intercourse or use another reliable form of
                  contraception approved by the Investigator (e.g., intrauterine device (IUD),
                  female condom, diaphragm with spermicide, cervical cap, use of condom by the
                  sexual partner or a sterile sexual partner) for 30 days prior to first
                  vaccination through 9 months after third vaccination

          -  Comprehension of the study requirements, as demonstrated by achieving a score of at
             least 80% correct on a short multiple-choice quiz.

               -  Individuals who fail to achieve a passing score on the initial comprehension
                  assessment will be given the opportunity to retest after a review of protocol
                  information.

               -  Individuals who fail the comprehension assessment for the second time will not be
                  enrolled.

          -  Available and able to participate in all planned study visits and procedures.

        Exclusion Criteria:

          -  History of malaria or previous receipt of an investigational malaria vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="P2">
          <title>10 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="P3">
          <title>30 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="P4">
          <title>100 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visits due to patient travel</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="B2">
          <title>10 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="B3">
          <title>30 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="B4">
          <title>100 µg + Alhydrogel</title>
          <description>Pfs25 VLP- FhCMB vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="8.93"/>
                    <measurement group_id="B2" value="36.7" spread="6.59"/>
                    <measurement group_id="B3" value="36.1" spread="8.96"/>
                    <measurement group_id="B4" value="30.6" spread="8.86"/>
                    <measurement group_id="B5" value="34.3" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With at Least One Adverse Event</title>
        <time_frame>336 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With at Least One Adverse Event</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Solicited Systemic Adverse Events</title>
        <time_frame>336 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Solicited Systemic Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Solicited Local Adverse Events</title>
        <time_frame>336 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP- FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Solicited Local Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Anti-Pfs25 IgG Following the Third Immunization.</title>
        <description>Serum anti-Pfs25 antibody IgG titers determined using an ELISA unit assay.</description>
        <time_frame>196 days</time_frame>
        <population>In the &quot;30 µg + Alhydrogel&quot; group, 15 out of 16 patient samples were analyzed as 1 patient in the group had withdrawn from the study by study day 196. In the &quot;100 µg + Alhydrogel&quot; group, 13 out of 16 patient samples were analyzed due to 2 patients in the group withdrawing from the study and an insufficient serum sample from a third patient.</population>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Anti-Pfs25 IgG Following the Third Immunization.</title>
          <description>Serum anti-Pfs25 antibody IgG titers determined using an ELISA unit assay.</description>
          <population>In the &quot;30 µg + Alhydrogel&quot; group, 15 out of 16 patient samples were analyzed as 1 patient in the group had withdrawn from the study by study day 196. In the &quot;100 µg + Alhydrogel&quot; group, 13 out of 16 patient samples were analyzed due to 2 patients in the group withdrawing from the study and an insufficient serum sample from a third patient.</population>
          <units>Antibody Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.2" lower_limit="19.0" upper_limit="1018"/>
                    <measurement group_id="O2" value="511.2" lower_limit="79.5" upper_limit="3287"/>
                    <measurement group_id="O3" value="492.9" lower_limit="202.4" upper_limit="1200"/>
                    <measurement group_id="O4" value="996.0" lower_limit="510.0" upper_limit="1942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance of IgG values at study day 196 as compared to day 0 (pre-immune).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance of IgG values at study day 196 as compared to day 0 (pre-immune).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</title>
        <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), one month after the second vaccination (Study Day 84) in either the 30 μg or 100 μg dose groups.</description>
        <time_frame>84 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</title>
          <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), one month after the second vaccination (Study Day 84) in either the 30 μg or 100 μg dose groups.</description>
          <units>% TRA</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.5" lower_limit="-106.4" upper_limit="54.7"/>
                    <measurement group_id="O4" value="4.3" lower_limit="-103.8" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</title>
        <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), showing ≥80% reduction of oocysts in Anopheles mosquito gut in ≥50% of the subjects with Study Day 196 sera (one month after the third vaccination) (Study Day 196) in either the 30 μg or 100 μg dose groups.</description>
        <time_frame>196 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O2">
            <title>10 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O3">
            <title>30 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
          <group group_id="O4">
            <title>100 µg + Alhydrogel</title>
            <description>Pfs25 VLP-FhCMB vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Transmission Reducing Activity (TRA) of Malaria Parasite</title>
          <description>Assessment of TRA, as measured by the standard membrane feeding assay (SMFA), showing ≥80% reduction of oocysts in Anopheles mosquito gut in ≥50% of the subjects with Study Day 196 sera (one month after the third vaccination) (Study Day 196) in either the 30 μg or 100 μg dose groups.</description>
          <units>% TRA</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="9.1" lower_limit="-92.1" upper_limit="56.9"/>
                    <measurement group_id="O4" value="22.5" lower_limit="-59.8" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <desc>196 days</desc>
      <group_list>
        <group group_id="E1">
          <title>2 µg + Alhydrogel</title>
          <description>Pfs25 VLP-FhCMB vaccine</description>
        </group>
        <group group_id="E2">
          <title>10 µg + Alhydrogel</title>
          <description>Pfs25 VLP-FhCMB vaccine</description>
        </group>
        <group group_id="E3">
          <title>30 µg + Alhydrogel</title>
          <description>Pfs25 VLP-FhCMB vaccine</description>
        </group>
        <group group_id="E4">
          <title>100 µg + Alhydrogel</title>
          <description>Pfs25 VLP-FhCMB vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In no event shall the PI publish or present, at any time, the data generated in the course of the performance of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jessica Chichester, Senior Scientist Immunology</name_or_title>
      <organization>Fraunhofer USA Center for Molecular Biotechnology</organization>
      <phone>302-369-3635</phone>
      <email>jessica.chichester@fhcmb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

